These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors. Uckert S; Stief CG Handb Exp Pharmacol; 2011; (204):307-22. PubMed ID: 21695646 [TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Uckert S; Oelke M Br J Clin Pharmacol; 2011 Aug; 72(2):197-204. PubMed ID: 21745238 [TBL] [Abstract][Full Text] [Related]
4. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract. Uckert S; Kuczyk MA Handb Exp Pharmacol; 2011; (202):527-42. PubMed ID: 21290241 [TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Wong P; Lawrentschuk N; Bolton DM Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210 [TBL] [Abstract][Full Text] [Related]
6. [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]. Becker AJ; Uckert S; Stief CG Urologe A; 2008 Dec; 47(12):1582-7. PubMed ID: 18854969 [TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. Gales BJ; Gales MA Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344 [TBL] [Abstract][Full Text] [Related]
8. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Uckert S; Hedlund P; Andersson KE; Truss MC; Jonas U; Stief CG Eur Urol; 2006 Dec; 50(6):1194-207; discussion 1207. PubMed ID: 16815627 [TBL] [Abstract][Full Text] [Related]
9. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Rosen RC; McKenna KE Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729 [TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677 [TBL] [Abstract][Full Text] [Related]
11. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. Tinel H; Stelte-Ludwig B; Hütter J; Sandner P BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354 [TBL] [Abstract][Full Text] [Related]
17. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631 [TBL] [Abstract][Full Text] [Related]
18. Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. Lee M Clin Ther; 2011 Nov; 33(11):1590-608. PubMed ID: 22036514 [TBL] [Abstract][Full Text] [Related]
19. Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract. Uckert S; Stief CG; Mayer M; Jonas U; Hedlund P World J Urol; 2005 Dec; 23(6):368-73. PubMed ID: 16331503 [TBL] [Abstract][Full Text] [Related]
20. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? Carson CC BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]